BioCardia (BCDA) announces that the United States Patent Office has granted US Patent No. 12,311,127 titled “Radial and Trans-endocardial Delivery Catheter”. US Patent No. 12,311,127 describes the Company’s minimally invasive interventional catheter systems to deliver biologic therapies to target sites in the heart. This minimally invasive delivery approach enables optimal, site-specific treatment, minimizes off-target toxicities, and avoids the need for surgical access to the heart. The allowed patent protects BioCardia’s helical needle-tipped catheter technology platform.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCDA:
- BioCardia’s Earnings Call: Progress Amid Financial Strain
- BioCardia Reports Positive Q1 2025 Progress
- BioCardia Advances Phase 3 CardiAMP HF II Trial
- BioCardia initiates patient enrollment at University of Wisconsin for study
- BioCardia announces first patient enrolled in Phase III CardiAMP HF II trial